‘No further action’ on eight matters and a caution on another matter are the latest results from the Australian Health Practitioner Regulation Agency (AHPRA) investigations into chemotherapy underdosing in Adelaide.
The investigations, pertaining to four medical practitioners and five pharmacists, relate to errors made at the Royal Adelaide Hospital and Flinders Medical Centre between 2014 and 2015.
As previously reported in the limbic, (see here) ten patients with AML were given incorrect doses of cytarabine prompting a 2016 review by the Australian Safety and Quality Commission. Four patients are known to have died since triggering coronial inquiries.
AHPRA said in a statement that ‘patients should feel safe in the health care they receive’ and that their findings did not negate the seriousness of the situation.
“No further action means that there is no current or ongoing risk to the public that a Board needs to manage,” AHPRA said.
“A caution is intended to act as a deterrent so that the practitioner does not repeat the conduct or behaviour.”
AHPRA said they were still investigating three of the most complex matters, which may result in regulatory action.
Local media have reported that two doctors have been stood down this week pending the outcome of a disciplinary process at the hospital.
AHPRA said three of the most complex matters were still under investigation and could result in regulatory action.